Aerospace and energy component maker’s calibrated growth strategy and peak utilization by FY28 drive buy ratings despite near-term moderation, Q3 EBITDA margin hits 39.2% India’s deepening integration into global aerospace has driven Azad Engineering into the frontline. Brokerages are upgrading or maintaining buy ratings based on a Rs 6,500 crore order book that provides multi-year … Read more
A 102% surge in defence revenue and Rs 11,130 crore executable order book offset margin pressure from tariffs as brokers upgrade ratings on multi-year growth visibility Bharat Forge is riding a defence-driven growth wave that is fundamentally reshaping its earnings profile. The auto ancillary and forging major delivered consolidated revenue of Rs 4,343 crore in … Read more
Strong Q3 performance and strategic restructuring push brokerages to maintain buy ratings with 20% upside as hospital margins hit 24.8% and pharmacy business nears breakeven Apollo Hospitals Enterprise is executing a transformation that goes well beyond quarterly earnings beats. India’s largest hospital chain delivered a consolidated EBITDA of Rs 9.7 billion in the third quarter … Read more
Infosys tells investors exactly how it plans to win the AI era – and analysts reckon the upside case is good Infosys held its AI Investor Day recently, and the message from management was unambiguous: it’s not another technology cycle to be managed, but a shift that the company intends to lead. Management sized the … Read more
Torrent Pharma delivered a textbook quarter — revenues up 18 per cent year-on-year to Rs 33 billion, profits climbing 26 per cent to Rs 6.4 billion, and EBITDA margins nudging up 40 basis points to 32.9 per cent. In the ordinary course of business, that would have been the headline. But this is no ordinary … Read more
A GST-driven margin surprise and accelerating sales has brokerages agree the growth story has legs Britannia Industries is back in a sweet spot. The country’s largest biscuit maker delivered a margin performance in Q3FY26 that surprised even optimistic analysts, while a new chief executive has arrived with an ambitious agenda of brand investment, inorganic acquisitions, … Read more
Pharma major’s 284 bps EBITDA margin gain and Unichem turnaround strategy draw bullish analyst calls IPCA Laboratories has emerged as a growth story in India’s pharmaceutical sector with two leading brokerages issuing buy recommendations following the company’s third-quarter performance that showcased margin expansion even as revenue growth remained modest. The Mumbai-based drugmaker’s ability to expand … Read more
A 50% revenue surge and 400% profit jump have made analysts sit up and take notice When a mid-cap jewellery stock delivers revenue growth of 50% and profit growth north of 400% in a single quarter, you’d expect analysts to be tripping over themselves. Senco Gold’s Q3FY26 results has driven BOB Capital Markets which has … Read more
Lupin has delivered the goods this quarter. When a pharmaceutical company beats estimates across revenue, margins, and profit in a single quarter, investors tend to sit up. When it does so by margins wide enough to force analysts to revise their numbers upward, the question shifts from “is this good?” to “is this sustainable?” Lupin … Read more
There is a particular kind of market injustice reserved for companies that do everything right at the wrong time. Jubilant Foodworks — the company that runs Domino’s Pizza in India and a growing international portfolio — just delivered a quarter that answered every question bears had been asking. Like-for-like growth held up on a … Read more